NCT07023445

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

Patterns of Inclisiran Use in the Real World: A Retrospective Analysis of US Databases

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 37,688 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a retrospective observational cohort study of patients who initiated inclisiran, alirocumab, or evolocumab in a real-world setting in the United States. The study used data extracted from three databases: (1) open and closed claims from Komodo's Healthcare map and electronic medical records (EMRs) from outpatient clinics affiliated with (2) Healix and (3) Metro Infusion Centers. The study period spanned from 01 January 2021 to the latest date of the available data for each database. Index date was defined as the date of the first claim for inclisiran, alirocumab, or evolocumab within the patient identification period. The 12-month period prior to the index date (including the index date) was the baseline period. Follow-up spanned from the index date up to patient disenrollment, death, or the end of the study period, whichever came first.

Conditions

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia

Timeline

• Start date: 2023-01-20
• Primary completion: 2024-06-28
• Completion: 2024-06-28
• First posted: 2025-06-17
• Last updated: 2025-06-17

Locations

1 site across 1 country: United States